KUALA LUMPUR, Feb 11 (Bernama) -- Samsung Bioepis Co Ltd has announced its expansion in mainland China through a licensing agreement with C-Bridge Capital to develop and commercialise next-generation biosimilars in the region.
The agreement covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12, which reference LUCENTIS (ranibizumab) and SOLIRIS (eculizumab), respectively, as well as SB3, a biosimilar candidate referencing HERCEPTIN (trastuzumab).
Under the initiative, C-Bridge will establish a new biopharmaceutical company, AffaMed Therapeutics. It will collaborate with Samsung Bioepis across a number of areas, including clinical development, regulatory registration and commercialisation in China.
According to a statement, Samsung Bioepis will receive an upfront payment and royalties on sales.
“We want to play an important role in widening access to high-quality healthcare for patients throughout China,” said Samsung Bioepis, president and chief executive officer, Christopher Hansung Ko, in the statement.
“C-Bridge is the right partner for this mission as evidenced in its exceptional track record of successfully turning portfolio companies like AffaMed Therapeutics into leading biopharmaceutical companies in China and beyond,” he added.
Established in February 2012, Samsung Bioepis currently has four biosimilars approved and marketed across Europe, one in the United States (US), while another biosimilar – ONTRUZANT (trastuzumab-dttb) – has been approved by the US Food and Drug Administration.
With over six million doses administered, over 100,000 patients worldwide are currently under treatment with Samsung Bioepis’ biosimilars. For more information, visit http://www.samsungbioepis.com.
-- BERNAMA
No comments:
Post a Comment